Did you know?
Approximately 45,000 premature deaths in the UK every year are due to CKD.1
Experts are urging for more to be done to:
- Support HCPs with the early detection of CKD and identifying opportunities for intervention.2
- Help patients recognise the signs of CKD and engage with CKD testing.3,4
As uncontrolled diabetes is one of the leading causes of CKD,1 it is crucial your T2D patients understand the importance of engaging with regular UACR and eGFR screenings, and are aware of any symptoms which could be cause for concern.
Download and print this patient leaflet to help your T2D patients understand "What has diabetes got to do with my kidneys?"
Proven efficacy vs placebo5,6
Demonstrated CV and kidney safety profile
Abbreviation:
CKD: chronic kidney disease; CV: cardiovascular; eGFR: estimated glomerular filtration rate; HCPs: healthcare professionals; T2D: type 2 diabetes; UACR: urine albumin-creatinine ratio
Footnotes
-
§
Treatment difference of 0.8% in favour of linagliptin for adjusted mean HbA1c reduction at 24-weeks between linagliptin and placebo groups.
-
*
CARMELINA® included 6,979 patients with albuminuria & previous macrovascular disease, and/or impaired kidney function with or without CV comorbidities. CAROLINA® included 6,033 patients with one or more of the following: a) previous vascular disease, b) evidence of vascular- related end-organ damage, c) age: ≥ 70 years and d) ≥ 2 CV risk factors (smoking, hypertension, T2D duration ≥ 10 years, dyslipidemia).
-
#
Pharmacokinetic studies suggest that no dose adjustment is required for patients with hepatic impairment but clinical experience in such patients is lacking.
-
†
Sulphonylureas and insulin are known to cause hypoglycaemia. Therefore, caution is advised when linagliptin is used in combination with a sulphonylurea and/or insulin. A dose reduction of the sulphonylurea or insulin may be considered.
References:
- Kidney Care UK (2026). Key facts about Kidneys. Available at: https://kidneycareuk.org/kidney-disease-information/about-kidney-health/facts-about-kidneys/ (accessed May 2026).
- Kidney Research UK (2024). Chronic kidney disease and prevention: Harnessing the potential of early intervention and disease management. Available at: https://www.kidneyresearchuk.org/wp-content/uploads/2023/03/Kidney-Research-report-on-prevention-and-early-detection.pdf (accessed May 2026).
- Diabetes UK (2018). Diabetes UK and Kidney Research UK joint statement. Available at: https://www.diabetes.org.uk/sites/default/files/2018-08/Diabetes%20UK%20%20Kidney%20Research%20UK%20joint%20research%20statement.pdf (accessed May 2026).
- Kidney Research UK (2020). Type 2 diabetics are missing out on an annual kidney test. Available at: https://www.kidneyresearchuk.org/2020/02/20/type-2-diabetics-are-missing-out-on-an-annual-kidney-test/ (accessed May 2026).
- Linagliptin Summary of Product Characteristics (SmPC). Available at EMC.
- Del Prato S, et al. J Diab Compl. 2013;27:274–279.
- Rosenstock J, et al. Cardiovasc Diabetol. 2018;17:39.
- Rosenstock J, et al. JAMA. 2019;321:69–79.
- Cooper M, et al. Diabetes Obes Metab. 2020;22:1062–73.
- Marx N, et al. Diab Vasc Res. 2015;12:164–74.
- Rosenstock J, et al. JAMA. 2019;322:1155–66.
- Espeland MA, et al. Diabetes Obes Metab. 2021;23:569–80.
- Lajara R, et al. Clin Ther. 2014;36:1595–605.
Linagliptin is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control
PC-GB-112448 | May 2026